Burden of lung cancer and predicted costs of occupational exposure to hexavalent chromium in the EU - The impact of different occupational exposure limits.

[1]  M. J. Silva,et al.  The HBM4EU chromates study - Outcomes and impacts on EU policies and occupational health practices. , 2022, International Journal of Hygiene and Environmental Health.

[2]  T. Vermeire,et al.  Occupational exposure to Cr(VI) in Finland in 1980-2016 and related lung cancer risk assessment. , 2022, Regulatory toxicology and pharmacology : RTP.

[3]  K. Straif,et al.  Occupational exposure to nickel and hexavalent chromium and the risk of lung cancer in a pooled analysis of case‐control studies (SYNERGY) , 2022, International journal of cancer.

[4]  S. Øverland,et al.  Estimating risk factor attributable burden – challenges and potential solutions when using the comparative risk assessment methodology , 2022, Archives of Public Health.

[5]  M. Sapienza,et al.  Cancers: What Are the Costs in Relation to Disability-Adjusted Life Years? A Systematic Review and Meta-Analysis , 2022, International journal of environmental research and public health.

[6]  G. Buitrago,et al.  Attributable Costs of Lung Cancer for the Colombian Health System: A Cost-of-Illness Study. , 2022, Value in health regional issues.

[7]  L. Godderis,et al.  HBM4EU Chromates Study: Determinants of Exposure to Hexavalent Chromium in Plating, Welding and Other Occupational Settings , 2022, International journal of environmental research and public health.

[8]  M. J. Silva,et al.  HBM4EU chromates study - Overall results and recommendations for the biomonitoring of occupational exposure to hexavalent chromium. , 2021, Environmental research.

[9]  Ravensara S. Travillian,et al.  Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2021, The Lancet. Respiratory medicine.

[10]  M. Gumus,et al.  Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective , 2021, Health Economics Review.

[11]  Z. Dai,et al.  Association of 13 Occupational Carcinogens in Patients With Cancer, Individually and Collectively, 1990-2017 , 2021, JAMA network open.

[12]  C. Geraldes,et al.  Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness , 2021, PharmacoEconomics.

[13]  N. Speybroeck,et al.  Burden of Disease Methods: A Guide to Calculate COVID-19 Disability-Adjusted Life Years , 2020, International Journal of Public Health.

[14]  Dan J Stein,et al.  Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[15]  Changsoo Kim,et al.  Estimating the disease burden of lung cancer attributable to residential radon exposure in Korea during 2006-2015: A socio-economic approach. , 2020, The Science of the total environment.

[16]  R. Leggett,et al.  A biokinetic model for trivalent or hexavalent chromium in adult humans , 2019, Journal of radiological protection : official journal of the Society for Radiological Protection.

[17]  W. Ahrens,et al.  Exposure to Welding Fumes, Hexavalent Chromium, or Nickel and Lung Cancer Risk. , 2019, American journal of epidemiology.

[18]  M. Schabath,et al.  Cancer Progress and Priorities: Lung Cancer , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[19]  S. Hutchings,et al.  Prioritising action on occupational carcinogens in Europe: a socioeconomic and health impact assessment , 2017, British Journal of Cancer.

[20]  M. Postma,et al.  Burden of Early and Advanced Breast Cancer in The Netherlands , 2016 .

[21]  S. Thongprasert,et al.  WILLINGNESS TO PAY FOR LUNG CANCER TREATMENT: PATIENT VERSUS GENERAL PUBLIC VALUES , 2015, International Journal of Technology Assessment in Health Care.

[22]  C. Jo,et al.  Cost-of-illness studies: concepts, scopes, and methods , 2014, Clinical and molecular hepatology.

[23]  N. Speybroeck,et al.  Calculating disability-adjusted life years to quantify burden of disease , 2014, International Journal of Public Health.

[24]  P. Demers,et al.  Trends in compensation for deaths from occupational cancer in Canada: a descriptive study. , 2013, CMAJ open.

[25]  P. Landrigan,et al.  Burden of Disease from Toxic Waste Sites in India, Indonesia, and the Philippines in 2010 , 2013, Environmental health perspectives.

[26]  A. Seidler,et al.  Systematic review and quantification of respiratory cancer risk for occupational exposure to hexavalent chromium , 2013, International Archives of Occupational and Environmental Health.

[27]  I. Oh,et al.  Health and economic burden of major cancers due to smoking in Korea. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[28]  I. Poliaček,et al.  Lung cancer incidence and survival in chromium exposed individuals with respect to expression of anti-apoptotic protein survivin and tumor suppressor P53 protein , 2010, European journal of medical research.

[29]  J. Siemiatycki,et al.  Lung cancer risk associated with occupational exposure to nickel, chromium VI, and cadmium in two population-based case-control studies in Montreal. , 2010, American journal of industrial medicine.

[30]  R. Anzion,et al.  Characterisation of exposure to total and hexavalent chromium of welders using biological monitoring. , 2008, Toxicology letters.

[31]  J. Bena,et al.  Hexavalent Chromium and Lung Cancer in the Chromate Industry: A Quantitative Risk Assessment , 2004, Risk analysis : an official publication of the Society for Risk Analysis.